Drugs / JNJ-74856665
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04609826 | Nov 2020 → Aug 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-74856665 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04609826 ↗ |
| Action | Inhibit | “JNJ-74856665 is an orally bioavailable, potent, and selective dihydroorotate dehydrogenase (DHODH) inhibitor” NCT04609826 ↗ |
| Route | Oral | “JNJ-74856665 will be administered orally.” NCT04609826 ↗ |
| Target | DHODH | “JNJ-74856665 is an orally bioavailable, potent, and selective dihydroorotate dehydrogenase (DHODH) inhibitor” NCT04609826 ↗ |